Table 2.

Univariate and multivariate analysis of factors associated with progression-free and overall survival following immune checkpoint inhibitor–based therapies.

Progression-free survivalOverall survival
HR (95% CI)PHR (95% CI)P
Univariate models (n = 62)
 High TMB0.46 (0.22–0.95)0.040.48 (0.22–1.05)0.07
PTEN alteration2.04 (1.15–3.63)0.012.19 (1.16–4.13)0.02
 ECOG PS1.72 (0.58–3.05)0.063.24 (1.74–6.04)0.0002
 Previous lines of therapy1.57 (0.91–2.71)0.111.39 (0.75–2.56)0.30
 Regimen1.31 (0.69–2.49)0.411.14 (0.57–2.26)0.72
 Visceral metastases1.10 (0.59–2.06)0.771.11 (0.56–2.20)0.77
High TMB multivariate model (n = 62)
 High TMB0.42 (0.19–0.93)0.030.54 (0.23–1.26)0.15
 ECOG PS1.64 (0.89–3.00)0.112.93 (1.53–5.63)0.001
 Previous lines of therapy1.57 (0.89–2.76)0.121.29 (0.68–2.45)0.43
 Regimen1.83 (0.90–3.73)0.101.54 (0.71–3.35)0.27
 Visceral metastases1.50 (0.79–2.86)0.221.35 (0.65–2.82)0.42
PTEN Alteration multivariate model (n = 62)
PTEN alteration2.71 (1.44–5.10)0.0023.26 (1.59–6.68)0.001
 ECOG PS1.98 (1.08–3.62)0.033.84 (1.99–7.39)0.00006
 Previous lines of therapy1.83 (1.02–3.29)0.041.57 (0.81–3.06)0.18
 Regimen1.84 (0.90–3.74)0.091.69 (0.78–3.62)0.18
 Visceral metastases1.21 (0.64–2.30)0.561.05 (0.52–2.14)0.88
High TMB and PTEN alteration multivariate model (n = 62)
 High TMB0.37 (0.17–0.80)0.010.48 (0.20–1.14)0.10
PTEN alteration3.07 (1.62–5.81)0.00063.44 (1.67–7.07)0.0008
 ECOG PS1.67 (0.91–3.05)0.103.34 (1.72–6.49)0.0004
 Previous lines of therapy1.79 (1.00–3.21)0.051.48 (0.76–2.87)0.25
 Regimen2.38 (1.15–4.96)0.022.05 (0.92–4.55)0.08
 Visceral metastases1.45 (0.75–2.78)0.271.28 (0.61–2.67)0.52
High TMB, PTEN alteration, and PD-L1 multivariate model (n = 37)
 High TMB0.37 (0.15–0.91)0.030.42 (0.16–1.11)0.08
PTEN alteration2.82 (1.16–6.85)0.022.93 (1.14–7.53)0.03
 PD-L10.78 (0.31–1.93)0.591.28 (0.48–3.43)0.63
 ECOG PS1.16 (0.47–2.87)0.742.27 (0.90–5.73)0.08
 Previous lines of therapy1.41 (0.62–3.18)0.411.39 (0.59–3.30)0.45
 Regimen1.18 (0.41–3.42)0.761.70 (0.58–4.97)0.33
 Visceral metastases0.71 (0.27–1.88)0.501.00 (0.39–2.59)0.99
  • Note: High TMB: ≥ 10 mutations/megabase vs. < 10 mutations/megabase; PTEN alteration (nonsynonymous mutation or 1 or 2 copy deletion): present vs. absent; PD-L1: positive vs. negative; ECOG PS: ≥ 1 vs. 0; Previous lines of therapy: ≥ 1 vs. 0; Regimen: monotherapy vs. combination therapy; Visceral metastases: present vs. absent.

  • Abbreviations: CI, confidence interval; ECOG-PS: Eastern Cooperative Oncology Group performance status; TMB, tumor mutational burden.